Table 2.

Characteristics of the tumour according to patients’ vital status^a (N = 6,981)

		Vital status at
		1 month			3 months
		Alive	Dead		Alive	Dead
	N	N = 6,303	N = 678	p-value	N = 5,360	N = 1,621	p-value
Histology		n = 6,303	n = 678		n = 5,360	n = 1,621
Small-cell carcinoma, n (%)	961	829 (13.2)	132 (19.5)	<0.001	725 (13.5)	236 (14.6)	0.309
Adenocarcinoma, n (%)	3,221	2,944 (46.7)	277 (40.9)	0.004	2,482 (46.3)	739 (45.6)	0.632
Squamous-cell carcinoma, n (%)	1,875	1,733 (27.5)	142 (20.9)	<0.001	1,488 (27.8)	387 (23.9)	0.002
Large-cell carcinoma, n (%)	786	665 (10.6)	121 (17.9)	<0.001	544 (10.2)	242 (14.9)	<0.001
Adenocarcinoma in situ, n (%)	77	72 (1.1)	5 (0.7)	0.444	67 (1.3)	10 (0.6)	0.045
Carcinoid tumour, n (%)	40	39 (0.6)	1 (0.2)	0.176 b	38 (0.7)	2 (0.1)	0.011
Other, n (%)	111	102 (1.6)	9 (1.3)	0.679	86 (1.6)	25 (1.5)	0.095
Genomic mutation		n = 6,237	n = 670		n = 5,301	n = 1,606
Explored, n (%)	2,111	1,969 (31.6)	142 (21.2)	<0.001	1,685 (31.8)	426 (26.5)	<0.001
If explored,		n = 1806	n = 121		n = 1,555	n = 372
EGFR mutated, n (%)	202	196 (10.9)	6 (5.0)	0.058	179 (11.5)	23 (6.2)	0.003
Stage (7 edition)		n = 6,264	n = 672	<0.001	n = 5,334	n = 1,602	<0.001
Stage ≤ IIB, n (%)	1,129	1,100 (17.6)	29 (4.3)		1,056 (19.8)	73 (4.6)
Stage IIIA, n (%)	934	905 (14.4)	29 (4.3)		845 (15.8)	89 (5.6)
Stage IIIB, n (%)	705	643 (10.3)	62 (9.2)		571 (10.7)	134 (8.4)
Stage IV, n (%)	4,168	3,616 (57.7)	552 (82.1)		2,862 (53.7)	1,306 (81.5)

^a1 and 3 months after the diagnosis of primary lung cancer (date of diagnosis = date of histological or cytological sampling);

^bFisher test (violation of Chi² test conditions)

N or n: number of subjects

Note: Significant p-value are in bold